| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
50,198 |
41,611 |
$4.15M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,261 |
14,968 |
$1.08M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
8,467 |
7,299 |
$752K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
7,888 |
6,673 |
$689K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
26,729 |
21,683 |
$458K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,353 |
4,486 |
$445K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
4,270 |
3,560 |
$405K |
| 99199 |
Unlisted special service, procedure or report |
103,639 |
88,355 |
$404K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
11,772 |
9,723 |
$320K |
| 99051 |
|
6,496 |
5,121 |
$142K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
15,711 |
13,019 |
$134K |
| 87428 |
|
2,419 |
1,721 |
$125K |
| D0145 |
Oral evaluation for a patient under three years of age |
3,433 |
3,101 |
$111K |
| 99215 |
Prolong outpt/office vis |
946 |
828 |
$106K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
883 |
605 |
$97K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,652 |
2,102 |
$89K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,489 |
2,879 |
$84K |
| 96127 |
|
19,373 |
15,893 |
$73K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
981 |
873 |
$66K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,606 |
2,206 |
$61K |
| D1206 |
Topical application of fluoride varnish |
3,391 |
3,070 |
$48K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,092 |
2,015 |
$28K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
515 |
422 |
$16K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
296 |
265 |
$10K |
| 36415 |
Collection of venous blood by venipuncture |
3,003 |
2,575 |
$7K |
| 90686 |
|
12,458 |
9,949 |
$7K |
| 90651 |
|
355 |
303 |
$7K |
| 90474 |
|
364 |
315 |
$7K |
| 80061 |
Lipid panel |
407 |
378 |
$6K |
| 92551 |
|
18,433 |
15,967 |
$6K |
| 94664 |
|
384 |
378 |
$4K |
| 90734 |
|
302 |
238 |
$4K |
| 88738 |
|
627 |
569 |
$3K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
355 |
336 |
$3K |
| 94060 |
|
106 |
71 |
$3K |
| 87807 |
|
266 |
204 |
$3K |
| 99173 |
|
19,715 |
17,111 |
$3K |
| 94010 |
|
108 |
92 |
$2K |
| 96160 |
|
670 |
344 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
93 |
91 |
$2K |
| 87420 |
|
126 |
125 |
$2K |
| 84439 |
|
156 |
141 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
183 |
156 |
$2K |
| 80053 |
Comprehensive metabolic panel |
159 |
157 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
138 |
118 |
$2K |
| 81003 |
|
833 |
754 |
$1K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
313 |
284 |
$824.36 |
| 99441 |
|
17 |
12 |
$403.76 |
| 83655 |
|
50 |
37 |
$383.00 |
| 90670 |
|
2,616 |
2,132 |
$235.49 |
| 85018 |
|
80 |
63 |
$187.09 |
| 3078F |
|
33,040 |
28,265 |
$115.34 |
| 85027 |
|
12 |
12 |
$87.78 |
| 3074F |
|
38,242 |
32,113 |
$42.41 |
| 90723 |
|
856 |
722 |
$0.00 |
| 90680 |
|
669 |
564 |
$0.00 |
| 3044F |
|
322 |
246 |
$0.00 |
| 90647 |
|
733 |
620 |
$0.00 |
| 90660 |
|
16 |
15 |
$0.00 |
| 3079F |
|
138 |
119 |
$0.00 |
| 90656 |
|
57 |
55 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
54 |
50 |
$0.00 |
| 90677 |
|
38 |
37 |
$0.00 |
| 90620 |
|
14 |
13 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
19 |
18 |
$0.00 |
| 36416 |
|
12 |
12 |
$0.00 |
| 90461 |
|
398 |
359 |
$0.00 |
| 90672 |
|
132 |
108 |
$0.00 |
| 90685 |
|
32 |
24 |
$0.00 |
| 90633 |
|
98 |
88 |
$0.00 |
| G9919 |
Screening performed and positive and provision of recommendations |
62 |
48 |
$0.00 |
| 90710 |
|
103 |
90 |
$0.00 |